Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport[s]

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 670-681

  Cai, Xiaokun ^a   Bikadi, Zsolt ^a,b   Ni, Zhanglin ^a   Lee, Eun Woo ^a,c   Wang, Honggang ^a   Rosenberg, Mark F ^d   Mao, Qingcheng ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Virtua Drug Ltd   (Hungary)

^c Dong Eui University   (South Korea)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATASE; ALANINE; AMINO ACID; ARGININE; ASPARTIC ACID; BORON; BREAST CANCER RESISTANCE PROTEIN; HISTIDINE; HOE 33342; LYSINE; MEMBRANE PROTEIN; MITOXANTRONE; MUTANT PROTEIN; PRAZOSIN; TRYPSIN;

AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DEGRADATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; KIDNEY CELL; MOLECULAR DOCKING; MOLECULAR MODEL; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ADENOSINE TRIPHOSPHATASES; ADRENERGIC ALPHA-ANTAGONISTS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOTTING, WESTERN; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLOW CYTOMETRY; HUMANS; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEOPLASM PROTEINS; PHARMACEUTICAL PREPARATIONS; PRAZOSIN; PROTEIN BINDING; PROTEIN CONFORMATION; TRANSFECTION; XENOBIOTICS;

EID: 77952335476     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.163493     Document Type: Article

References (37)

1. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
2. Alqawi O, Bates S, and Georges E (2004) Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. Biochem J 382:711-716.
3. Bikadi Z and Hazai E (2009) Application of the PM6 semiempirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform 1:15.
4. Clark R, Kerr ID, and Callaghan R (2006) Multiple drug binding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149:506-515.
5. Conseil G, Deeley RG, and Cole SP (2006) Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). J Biol Chem 281:43-50.
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
7. Ejendal KF, Diop NK, Schweiger LC, and Hrycyna CA (2006) The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci 15:1597-1607.
8. Honjo Y, Hrycyna CA, Yan QW, Medina-Pérez WY, Robey RW, van de Laar A, Litman T, Dean M, and Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-6639.
9. Huey R, Morris GM, Olson AJ, and Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-1152.
10. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, and Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
11. Koike K, Conseil G, Leslie EM, Deeley RG, and Cole SP (2004) Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. J Biol Chem 279:12325-12336.
12. Leslie EM, Létourneau IJ, Deeley RG, and Cole SP (2003) Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42:5214-5224.
13. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
14. Mao Q, Conseil G, Gupta A, Cole SP, and Unadkat JD (2004) Functional expression of the human breast cancer resistance protein in Pichia pastoris. Biochem Biophys Res Commun 320:730-737.
15. Mao Q and Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J 7:E118-E133.
16. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, Ford RC, and Callaghan R (2006) Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14:1623-1632.
17. Merino G, Real R, Baro MF, Gonzalez-Lobato L, Prieto JG, Alvarez AI, and Marques MM (2009) Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors. Drug Metab Dispos 37:5-9.
18. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, and Ishikawa T (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 373:767-774.
19. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, and Sugimoto Y (2003) Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross-resistance patterns in transfectants. Int J Cancer 107:757-763.
20. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, et al. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13.
21. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, and Ross DD (2003) Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 64:1452-1462.
22. Ozvegy-Laczka C, Köblös G, Sarkadi B, and Váradi A (2005) Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 1668:53-63.
23. Ozvegy-Laczka C, Laczkó R, Hegedus C, Litman T, Várady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Váradi A, et al. (2008) Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem 283:26059-26070.
24. Polgar O, Ediriwickrema LS, Robey RW, Sharma A, Hegde RS, Li Y, Xia D, Ward Y, Dean M, Ozvegy-Laczka C, et al. (2009) Arginine 383 is a crucial residue in ABCG2 biogenesis. Biochim Biophys Acta 1788:1434-1443.
25. Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, et al. (2006) Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Biochemistry 45:5251-5260.
26. Popot JL and Engelman DM (2000) Helical membrane protein folding, stability, and evolution. Annu Rev Biochem 69:881-922.
27. Pozza A, Perez-Victoria JM, Sardo A, Ahmed-Belkacem A, and Di Pietro A (2006) Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cell Mol Life Sci 63:1912-1922.
28. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003) Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978.
29. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, and Bates SE (2001) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171-182.
30. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61:3-13.
31. Ryu S, Kawabe T, Nada S, and Yamaguchi A (2000) Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J Biol Chem 275:39617-39624.
32. Stewart JJ (2009) Application of the PM6 method to modeling proteins. J Mol Model 15:765-805.
33. Taguchi Y, Kino K, Morishima M, Komano T, Kane SE, and Ueda K (1997) Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. Biochemistry 36:8883-8889.
34. Vethanayagam RR, Wang H, Gupta A, Zhang Y, Lewis F, Unadkat JD, and Mao Q (2005) Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 33:697-705.
35. Wang H, Lee EW, Cai X, Ni Z, Zhou L, and Mao Q (2008) Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry 47:13778-13787.
36. Xu J, Liu Y, Yang Y, Bates S, and Zhang JT (2004) Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279:19781-19789.
37. Xu J, Peng H, Chen Q, Liu Y, Dong Z, and Zhang JT (2007) Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res 67:4373-4381.